Moderna, Inc. (MRNA)
| Market Cap | 10.16B |
| Revenue (ttm) | 3.18B |
| Net Income (ttm) | -3.36B |
| Shares Out | 386.74M |
| EPS (ttm) | -8.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,218,861 |
| Open | 26.15 |
| Previous Close | 26.72 |
| Day's Range | 25.55 - 26.49 |
| 52-Week Range | 23.15 - 170.47 |
| Beta | 2.00 |
| Analysts | Hold |
| Price Target | 48.13 (+83.28%) |
| Earnings Date | May 1, 2025 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $48.13, which is an increase of 83.28% from the latest price.
News
Moderna files application for updated COVID vaccine
Moderna said on Friday it had filed a marketing application for an updated COVID vaccine to the U.S. Food and Drug Administration.
Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine
CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spike...
Moderna withdraws application for COVID-flu combination vaccine
Moderna said on Wednesday it had withdrawn the pending application for its flu and COVID combination vaccine candidate for adults aged 50 years and older.
Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19
CAMBRIDGE, MA / ACCESS Newswire / May 21, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company has voluntarily withdra...
Top Stock Movers Now: Viking, Moderna, Uber Technologies, and More
U.S. equities were lower at midday, dragged by tech and travel stocks. The Dow Jones Industrial Average, S&P 500, and Nasdaq were all lower.
Moderna: After A Crash From $500 To $25, I'm Buying This "Call Option" On Pandemics And Cancer
Moderna's share price has collapsed from $500 to $25, but I believe the selloff is overdone, and the stock is deeply oversold. Short squeeze potential, a robust pipeline, and long-term mRNA/AI opportu...
S&P500 and Nasdaq Index: Consumer Data Sinks Sentiment, Super Micro, Moderna Rally
S&P 500 and Nasdaq edge higher mid-session as weak sentiment data tempers gains. Traders assess inflation risks and tariff uncertainty.
Why Moderna Merged Its Tech and HR Departments
The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the growing capabilities of AI and other tech.
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic Decision...
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell
Moderna's Q1 earnings reveal a significant revenue decline and high cash burn, driven by reduced demand for its COVID-19 vaccine and inventory write-downs. Regulatory setbacks for Moderna's combinatio...
Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026
Moderna Inc. MRNA reported on Thursday a first-quarter EPS loss of $(2.52), missing the consensus of $(3.12), down from an EPS loss of $(3.07) a year ago.
Moderna, Inc. (MRNA) Q1 2025 Earnings Call Transcript
Moderna, Inc. (NASDAQ:MRNA) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive ...
Moderna Posts Loss, Citing Seasonality of Respiratory Business
Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during cold and flu season later this year.
Moderna beats Wall Street estimates for first-quarter profit and sales
Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's cost-cutting efforts following waning post-pandemic demand for its COVID-19 vaccine...
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of...
Moderna Earnings Arrive During a Tough Time for the Stock
Moderna shares are down more than 30% this year, and around 75% over the past 12 months.
33 Stocks That Could Rally 50% or More This Year
Analysts say these S&P 500 stocks have at least 50% price upside over the next year or so.
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report ...
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influ...
Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter
Major pharmaceutical companies reap most of their profits in the U.S. but shift their tax burdens to low-tax havens such as Ireland.
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
S&P 500 Gains and Losses Today: Moderna Stock Plunges After Resignation of FDA Vaccine Official
Major U.S. equities indexes were mixed to kick off the new trading week as U.S. trade policy remained in focus.
S&P 500 recoups losses, Dow rises as volatile March ends; Newsmax surges, Moderna tanks
Investors were nervous about US President Donald Trump's tariff plans, which caused the S&P 500 to fall on Monday and enter correction territory. However, the index recovered its losses from earlier ...